Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SpectRx

This article was originally published in The Gray Sheet

Executive Summary

Diabetes management firm sells BiliChek noninvasive bilirubin analyzer product line to sleep apnea firm Respironics for use in monitoring infant jaundice. Respironics will pay a base purchase price of $4 mil., another $1 mil. after the completion of product development, and an additional $6.25 mil. over five years in royalties and earn out payments based on realized revenues. BiliChek predicts the level of bilirubin, which causes infant jaundice, by assessing the amount of light reflected off the forehead and will be an alternative to taking blood from the heel and waiting for lab results. SpectRx is divesting the product to focus on development of a continuous glucose monitor...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT018018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel